Given the complexities of predicting outcomes in high-risk melanoma treated with adjuvant anti–PD-1 therapy, our study aimed to explore both recurrence under therapy and RFS in relation to a set of clinical and pathological variables. Here, PDCD1 is linked to melanoma.